PPT-Prostate Cryotherapy Minimally Invasive Cancer Treatment

PM3590 Rev A 0811 This information is intended for general patient education purposes only in consultation with a physician What is Cryotherapy Cryotherapy Cryoablation Cryosurgery Tissue Ablation destruction through the localized delivery of extreme cold. Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. Ruth Etzioni. Roman Gulati . Lurdes . inouE. Dhamanpreet. Kaur. Fred Hutchinson cancer research center. TODAY’S PRESENTATION. Trends in prostate cancer incidence and mortality. What are the trends really telling us? A mathematical model. CÉSAR DAVID VERA-DONOSO. Department. of . Urology. WHO IS IN THE LINE OF FIRE?. WE NEED TO COLLABORATE IN MANY FIELDS. WE NEED RELIABLE IMAGES TO TAKE DECISIONS. INCIDENCE. EUROPE. In Europe, . PCa. Prostate Cancer . C. Ryan Barnes, MD. Virginia Urology. Active Surveillance. Hormone therapy. Radical prostatectomy. Open. Laparoscopic (with or without a robot). Brachytherapy (seed implantation). External beam radiation.  . Prof. Serdar Gunaydin, MD, PhD. 1. Kevin. . McCusker. , CCP,PhD. 2. Department of Cardiac Surgery, University of Health Sciences, Ankara- Turkey. 1. and New York Medical College, Valhalla, NY. 1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, et al. JAMA . Oncol. . 2015; 1(4): 505-27/ 2. . Droz. JP, et al. Lancet . Oncol. . 2014; 15(9): e404-14/ 3. . Cuzick. J, et al. Lancet . 1 Brachytherapy Treatment for Prostate Cancer One of the side effects is erectile dysfunction. It may not be suitable for men who already have urinary problems. Urinary problems such as incontinenc Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, –. To treat . or not to treat. Dr Oliver Klein – Medical Oncologist. Prostate Cancer. |. . Epidemiology- Australia. Most common cancers 2012 . Cancer related deaths 2010 . Australian Institute of Health and Welfare. Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. By: Ishan Parikh. Symptoms. Be on the look out for…. “stop-and-go” flow of urine. Sudden urges to urinate. Frequent urination (esp. at nights). Trouble starting urination. Trouble with emptying bladder completely. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. NASPCC 10-13-18. Ronald Chen, MD MPH. Associate Professor, Radiation Oncology. University of North Carolina – Chapel Hill. Associate Director, UNC Lineberger Comprehensive Cancer Center. Disclosures.